At a glance
ClinicalIndex Comparison RecordN/ACompleted· 27,606 enrolled
Drug / intervention
Olodaterol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug Utilization Study for Olodaterol
In Brief
An observational study evaluating Olodaterol and Indacaterol for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 27,606 participants across 3 sites in 3 countries.
Detailed Summary
This study aims to characterise the use of single-agent olodaterol and single-agent indacaterol, the only marketed long-acting beta2-agonist (LABA)s authorised for chronic obstructive pulmonary disease (COPD), but not for asthma, in clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesDenmark, France, Netherlands
CollaboratorsRTI Health Solutions
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartFeb 2017
Primary CompletionMar 2018
TodayJul 2026
First PostedJan 25, 2017
Enrollment StartFeb 8, 2017
Primary CompletionMar 31, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.4 years ago
Interventions
Olodateroldrug
Drug
Indacateroldrug
Drug